The AHA July 20 submitted comments on proposed Centers for Medicare & Medicaid Services regulations that would support state flexibility in Medicaid drug value-based purchasing arrangements and other changes to the Medicaid drug rebate program for fiscal year 2021.

“The AHA supports innovations in drug purchasing arrangements, so long as these arrangements preserve or enhance patient access to critical medications and result in lower drug costs,” AHA wrote. “As CMS continues to pursue an increase in VBP opportunity, we urge the agency to consider the appropriate balance that must be struck to make these arrangements work effectively for the Medicaid program as well as throughout the health care delivery system.”

AHA also urged the agency to extend the comment period beyond the current 30-day period to allow stakeholders’ thoughtful and careful consideration for assessing the implications of applying VBP arrangements for Medicaid drug coverage and purchasing.

Related News Articles

Headline
The House Energy and Commerce Subcommittee on Health Feb. 29 held a hearing on legislative proposals to expand access to treatment for patients with rare…
Headline
The Centers for Medicare & Medicaid Services Feb. 20 finalized proposed changes to how states calculate the hospital-specific cap for Medicaid…
Perspective
Two presidents that America honors with a federal holiday on Monday shared a number of memorable traits. George Washington and Abraham Lincoln were blessed…
Headline
The AHA, joined by five other national associations representing hospitals, Feb. 2 urged the U.S. Supreme Court to review a case challenging how the Department…
Headline
The Medicaid and CHIP Payment and Access Commission (MACPAC) last week recommended seven changes to Medicaid managed care policy to better monitor denials and…
Headline
In an interview Jan. 17 in the Washington Post’s Health 202 newsletter, AHA President and CEO Rick Pollack explains why ‘site-neutral’ Medicare proposals…